Results 241 to 250 of about 5,569,467 (288)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Linear psoriasis unresponsive to multiple biological therapies (anti-TNF, anti-IL-12/23, and anti-IL-23): a case report. [PDF]

An Bras Dermatol
Romero-Romero S, Iglesias-Sancho M, Martin-Poch A, Salleras-Redonnet M.   +3 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms. [PDF]

Drugs Context
Dattola A, Bernardini N, Anedda J, Atzori L, Bonifati C, Bruni PL, Giordano D, Graceffa D, Molinelli E, Moretta G, Mugheddu C, Offidani A, Pagnanelli G, Pallotta S, Papini M, Persechino S, Richetta AG, Tolino E, Trovato F, Pellacani G, Potenza C.   +20 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Synergistic exacerbation of oral mucositis caused by IL-23 deficiency and oral <i>Candida albicans</i> exposure. [PDF]

mBio
Dillon JT, Hickey MT, Saul-McBeth J, Glanz T, Daboul Y, Byreddy YR, Hohl R, Kratch JM, Thakker JA, Gaffen SL, Gibbs J, Conti HR.   +11 more
europepmc   +1 more source

Serotonin 2A receptor attenuates psoriatic inflammation by suppressing IL-23 secretion in monocyte-derived Langerhans cells. [PDF]

Nat Commun
Tan YF, Yeh CY, Hsu SY, Lu CH, Tsai CH, Chiang PC, Weng HJ, Tsai TF, Lee YL.   +8 more
europepmc   +1 more source

Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. [PDF]

J Clin Med
Pedicelli A, Bessissow T, Afif W.
europepmc   +1 more source

De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy. [PDF]

Inflamm Intest Dis
Shiomi C, Kurokawa K, Ihara S, Nishioka Y, Akamatsu N, Bujo C, Hatano M, Ishida J, Hayakawa Y, Tsuji Y, Hasegawa K, Takeda N, Ono M, Kato J, Fujishiro M.   +14 more
europepmc   +1 more source

Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany. [PDF]

J Clin Med
Farrag K, Grimm L, Dahmer I, Stratmann K, Dienethal A, Sprinzl K, Lande R, Zeuzem S, Blumenstein I, Kubesch A.   +9 more
europepmc   +1 more source